β-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer.

ABSTRACT: K-ras mutation and p53 loss are the most prevalent genetic alterations in pancreatic cancer. In addition to these two alterations, pancreatic tumors frequently contain a third genetic defect. Mutations in the WNT/ß-catenin signaling molecules occur in 15-20% of pancreatic cancer patients and co-exist with K-ras mutation and p53 loss. However, the contribution of the WNT/ß-catenin pathway in pancreatic tumorigenesis is still unclear. Methods: We generated Pdx1-CreKras^G12Dp53^L/+APC^L/+ (KPA) mice and compared their phenotypes with Pdx1-CreKras^G12Dp53^L/+ (KPC) mice. The signaling pathways specifically activated in the KPA mice were investigated and the therapeutic effect by targeting the act

SUBMITTER: Kuo TL 

PROVIDER: S-EPMC6376185 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature